# A Phase IV-Pharmacovigilance Study of Keppra Greece - S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy

> **NCT00631150** · PHASE4 · COMPLETED · sponsor: **UCB Pharma** · enrollment: 35 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** Levetiracetam (Keppra)

## Key facts

- **NCT ID:** NCT00631150
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-03
- **Primary completion:** 2004-07
- **Final completion:** 2004-07
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2013-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00631150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00631150, "A Phase IV-Pharmacovigilance Study of Keppra Greece - S.K.A.T.E.: Safety of Keppra as Adjunctive Therapy in Epilepsy". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00631150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*